These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 6733045)

  • 1. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The characteristics of anticoagulation by covalently immobilized heparin.
    Miura Y; Aoyagi S; Kusada Y; Miyamoto K
    J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PGI2 on the inactivation of thrombin, factor Xa, and plasmin by antithrombin-III and heparin.
    Blaskó G
    Prostaglandins; 1979 Jul; 18(1):3-9. PubMed ID: 160589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 8. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
    Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
    Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

  • 12. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation.
    Kjalke M; Monroe DM; Hoffman M; Oliver JA; Ezban M; Roberts HR
    Thromb Haemost; 1998 Oct; 80(4):578-84. PubMed ID: 9798973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
    Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
    Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.